Daily Archives: April 17, 2018

Danal Wins 2018 Trailblazer Award at the KNOW Identity Conference

https://danalinc.com/danal-wins-2018-trailblazer-award-for-pioneering-mobile-identity-globally/

SAN JOSE, Calif., April 17, 2018 (GLOBE NEWSWIRE) — Danal won the 2018 Trailblazer Award in recognition of its ability to offer a high capacity mobile identity and authentication platform across the globe and to a variety of the world’s biggest brands. Presented at the KNOW Identity Conference (hosted by One World Identity) held in Washington, D.C. between March 26th to 28th, the award recognized Danal as the company which pushed boundaries and accomplished what industry insiders once considered impossible.

The “Trailblazer” award honors the organization that achieved the most unique and original solution to an existing identity challenge. Danal is empowering enterprises across various verticals such as financial institution, healthcare, marketplaces, e-commerce, hospitality, etc. to complete the “Mobile First” transformation globally. This transformation relies heavily on the consumer’s mobile phone number which is becoming the primary identifier across the globe.

This is precipitating a global democratization of identity using the phone number at its core, which traditionally has been the privilege of developed nations with national ID schemes. It is especially critical now when these traditional knowledge-based ID methods have succumbed to rampant data breaches.

Danal’s unique ability to utilize deep mobile network signals to accurately verify the phone number with the registered mobile device and the consumer owning it, enables these enterprises (Danal’s clients) to address remote online and POS (point of sale) challenges such as authentication, acquisition, fraud prevention and compliance. Furthermore, Danal’s platform amplifies the value by enabling an uninterrupted consumer experience, which historically has been disruptive with use of SMS with pin-code and other step-up techniques.

“It’s rewarding to be recognized as trailblazers in this industry by OWI, who has become the ‘Nexus of Identity’,” said Jim Greenwell, CEO at Danal Inc. “Many of the customer’s Identity requirements are in countries that are exclusively being solved by Danal’s global real-time Mobile Identity Platform thereby setting Danal apart from all others in the industry. Danal’s growing demand has led to the continued expansion into the NA, EMEA, LATAM, and APAC markets.”

About Danal
Danal, Inc. is the premier global provider of mobile identity and authentication solutions driven by unique real-time connections to mobile operator networks and data. Danal’s patented technology solves for multiple use cases across various industry verticals such as financial institution, healthcare, marketplaces, e-commerce, hospitality, etc. The supported use cases range from solving for compliance (GDPR, KYC, AML, TCPA, etc.), Identity proofing (computer vision, video streaming, biometrics and machine learning) during registration, high-value transactions and access control plus user experience improvements (auto form-fill, instant enrollment, guest check-out, etc.) and fraud prevention (account takeover, SIM fraud, device spoofing, malwares, etc.). Danal, Inc. is a privately held US company whose investors include Discover Financial Services, Morgenthaler Group, Orange Telecom, Bangkok Bank and Danal Co, Ltd.

Contact Information:
marketing@danalinc.com or Get in Touch

GoldCrypto Guarantees its Cryptocurrency Against Theft – A World First

PANAMA CITY, Panama, April 17, 2018 (GLOBE NEWSWIRE) — via NetworkWire — GoldCrypto.io (through its Service Operator Crypto Investor, Inc.) is pleased to advise:

In a world first, GoldCrypto is protecting and guaranteeing its cryptocurrency tokens from any theft through hacking. In the unlikely event of any hacking theft, stolen tokens will be replaced. This positions GoldCrypto AuX tokens as a better than bank-standard cryptocurrency.

GoldCrypto offers a gold-backed token with over a 50% premium in physical gold that keeps increasing over time. As well as having this token protected from hacking theft, it presents a rock-solid entry into the gold and cryptocurrency markets that is unmatched anywhere.

Through this innovation, GoldCrypto participants will benefit from bank-standard token (account) protection as well as 50%-plus leverage in gold-backing at initial commencement.

The GoldCrypto cryptocurrency security initiative is being implemented through the CryptoSecure Cryptocurrency Platform, which makes hacking and theft of tokens futile. Stolen tokens are rendered worthless in the hands of any cybercriminal and replaced into the victim’s account. For more information on the security platform, visit: www.cryptosecure.com.

GoldCrypto pre-purchases the gold bullion backing its AuX tokens through the Key Capital Corporation (OTC: KCPC) Mining Division. GoldCrypto has already pre-purchased over 13,000 ounces of gold. The Key Capital Mining Division team of specialists will monitor gold production from various mining interests through production, minting at Scottsdale Mint, and the final delivery to GoldCrypto-appointed vault storage. For more information on Key Capital Corporation, visit: https://keycapitalgroup.com

GoldCrypto AuX tokens feature the following as the ultimate stand-out cryptocurrency:

  • Safe and secure. If hacked (unlikely), stolen GoldCrypto AuX tokens are replaced
  • Backed by physical gold – starting at over US$0.30 in value per token
  • A better than gold-standard cryptocurrency
  • Gold backing continually increasing
  • Transparent blockchain
  • Decentralized and nationless
  • AuX tokens exchangeable for physical gold
  • Better than Bitcoin – AuX, the future of money

In a cryptocurrency market where hacking and token theft is rampant, AuX tokens represent a major industry breakthrough providing utility, value, and security.

GoldCrypto ICO

The Pre-ICO’s offering of a 15% bonus is open until April 30, 2018. AuX tokens can be secured through exchange for BTC, ETH, LTC, BTC Cash, ETH Classic, Dash, or PayPal.  For details, visit: https://goldcrypto.io

Contact Information

GoldCrypto Inquiry:
General Inquiries via info@goldcrypto.io
Darcy Johnston via darcy@cryptoinvestorinc.com

Institutional GoldCrypto Inquiry:
Ryan Lee via ryan@cryptoinvestorinc.com

Key Capital Corporation Inquiry:
Chris Nichols via info@keycapitalgroup.com

China Unicom Teams with Cisco to Enable Cloud + Network Synergy with Segment Routing

BEIJING, April 17, 2018 (GLOBE NEWSWIRE) — Recently, China United Network Communications Group Co., Ltd. (China Unicom) officially announced seven new products: Cloud Network Connection, Cloud Networking, Cloud VPV, Cloud Broadband, Unicom Cloud Shield, Intelligent Boutique Video Network, and Boutique Financial Network. China Unicom has achieved a major milestone in pursuing network transformation based on Industrial Internet and has become one of the leading service providers in building “cloud + network” synergy.

Cisco has been collaborating with China Unicom for the past two years, to transform the existing traditional nationwide MPLS VPN network into Industrial Internet with the “cloud + network” synergy based on Segment Routing. This project marks a series of firsts:

  • China’s first Segment Routing deployment in a service provider’s backbone network;
  • the first case of interconnecting equipment from multiple vendors supporting Segment Routing;
  • the first case of achieving high availability (HA) with controllers from multiple vendors

Industrial Internet is a concept derived from Consumer Internet. It refers to the practice of traditional industries leveraging the advantage of big data, cloud computing, smart devices and networks to increase internal efficiency and the ability to provide service for external customers. It is one of the most important ways for traditional industries to realize transformation and upgrade through “Internet+”.

China Unicom sharply discovered the tremendous opportunity of Industrial Internet and worked on it as a corporate strategy to build China’s first on-demand network that provides network routes with minimal latency for customers, supporting minute-level service launch. However, China Unicom’s nationwide MPLS VPN backbone network covers 300 cities with more than 1200 devices, and once it is connected with the IP RAN/SPDC metro network in the future, there will be tens of thousands of devices involved. In addition, “cloud + network” integration requires the ability to provide traffic engineering service for each tenant and each application. This presents an unprecedented challenge to network scalability. None of these issues can be solved by traditional RSVP-TE.

Segment Routing inherent benefits of network simplification, massive scalability and cross-domain operations support perfectly fit with China Unicom’s needs. Interoperability between vendors’ devices and controllers was a mandatory requirement.

Cisco used the ASR 9000 router series as the Provider Edge router (PE router), and went beyond traditional third-party equipment (using the static Segment Routing solution) to realize the connection of SRTE. As part of the overall solution, Cisco provided its Network Services Orchestrator (NSO) and WAN Automation Engine (WAE), participated in activities such as business modeling, equipment configuration, topology information collection and route calculation for Cisco and third-party equipment, and successfully delivered a multi-vendor Segment Routing solution.

Cisco also worked with China Unicom to drive and achieve high availability (HA) with multiple vendors’ SDN controllers. The system can monitor the condition of the master controller. When the master controller fails, the backup controller from a different vendor can smoothly take over all the business models, business examples, as well as configuration and route information, so as to complete the switching. This innovation is of utmost importance for upcoming 5G/large-scale SDN deployment.

Cisco’s Advanced Services teams played a major role in the implementation phase of the project. To align with China Unicom’s business strategy, Cisco did some “joint development” and customized development through a “three-step” strategy — consulting, implementation, and optimization. Cisco’s solution support team acted as the single Point of Contact (PoC) coordinating with related suppliers to follow up and screen problems, and the time needed to solve problems was reduced by 43%.

Ma Jichun, chief engineer from the digital department of China Unicom’s design institute CITC, said: “In the context of the new era, China Unicom strives to work with its partners to build a ‘cloud + network’ ecosystem by actively adopting SDN, NFV, cloud computing, Ultra-broadband Network and other technologies. There is a broad space for China Unicom and Cisco to engage in close collaboration and work together to develop leading technologies such as Segment Routing and SDN. China Unicom will build future networks with an open attitude, to better meet the new needs of customers.”

Jonathan Davidson, Senior Vice President and General Manager of Service Provider Networking at Cisco said: “Cisco and China Unicom have worked to transform its networking model and rebuild an intent-based next-generation network. Our collaboration is Cisco’s first Segment Routing deployment case in China involving technology from multiple vendors. We look forward to continuing our joint innovative practices, working together to drive the strategic layout and coordinated development of Industrial Internet.”

Cisco is leading the disruption in the industry with its technology innovations in systems; silicon; software and security; and its unrivalled expertise in mass-scale networking, automation, optical, optics, cable access, video, and mobility. Combining these capabilities with Cisco’s portfolio of go-to-market security, collaboration, IoT, and professional services, we enable service providers, media and web companies to reduce cost and complexity, help secure their networks, and grow revenue.

Supporting Resources

About China Unicom
China Unicom has branch organizations in 31 Chinese provinces (autonomous regions and municipalities) as well as multiple countries and regions outside of China. It is China’s only telecom service provider listed on New York City, Hong Kong and Shanghai at the same time. China Unicom ranked No.241 on the 2017 Fortune Global500 list.

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow’s digital opportunity today. Discover more at thenetwork.cisco.com and follow us on Twitter at @Cisco.

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds

Sara Cicero
Sr. Public Relations Manager
Cisco
Service Provider Business
770-236-2181 direct
770-331-0269 cell

AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting

Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 ≥25% and <25% groups in 2nd-line non-small cell lung cancer

Phase I Study 10 data shows clinical activity with combination treatment in 2nd-line metastatic urothelial carcinoma

CAMBRIDGE, United Kingdom, April 16, 2018 (GLOBE NEWSWIRE) — AstraZeneca and MedImmune, its global biologics research and development arm, today presented efficacy and safety data from two Phase I trials evaluating Imfinzi (durvalumab) in combination with tremelimumab in 2nd-line immunotherapy-naïve patients with either non-squamous advanced non-small cell lung cancer (NSCLC) (Study 006) or metastatic urothelial carcinoma (mUC) (Study 10).1,2 The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The mature data sets from these Phase I trials help further characterise the overall survival of durvalumab plus tremelimumab combination in 2nd-line non-squamous non-small cell lung cancer and 2nd-line metastatic urothelial carcinoma. We look forward to exploring whether OS is distinguished from durvalumab monotherapy in our Phase III MYSTIC and DANUBE trials, expected to read out later this year and next year, respectively.”

Study 006: Safety and activity of 2nd-line durvalumab + tremelimumab in non-squamous advanced NSCLC
The Study 006 long-term follow-up results showed clinical activity in both PD-L1 ≥25% and <25% groups.1 Tumour PD-L1 expression was assessed with the Ventana PD-L1 (SP263) assay, PD-L1 cut-off: ≥25% of tumour cells with membrane staining.1 The table below shows anti-tumour activity and survival by PD-L1 status.1

Response and survival PD-L1 ≥25%
N = 57
PD-L1 <25%
N = 136
Totala
N = 213
Complete Response (CR) 1 (1.8) 0 1 (0.5)
Partial Response (PR) 19 (33.3) 16 (11.8) 39 (18.3)
Stable Disease (SD) 17 (29.8) 55 (40.4) 77 (36.2)
Progressive Disease (PD) 16 (28.1) 52 (38.2) 77 (36.2)
Confirmed Objective Response Rate (ORR)
(CR + PR)

n (%)
95% CI
 20 (35.1)
22.9–48.9
16 (11.8)
6.9–18.4
40 (18.8)
13.8–24.7
Duration of Response (DOR)
Median, weeks
95% CI
 51.7
25.1–NE
NR
24.3–NE
51.7
40.3–NE
PFS
Median, months
95% CI
 7.1
3.4–9.2
 3.3
1.7–3.5
 3.5
1.8–4.0
OS
12-month OS, %
95% CI
71.6
57.3–81.9
 47.3
38.2–55.9
 53.8
46.4–60.6
Note: Investigator-assessed anti-tumour activity according to RECIST v1.1. NE, not estimable.
a20 patients had unknown PD-L1 expression

The combination of durvalumab and tremelimumab demonstrated a manageable safety profile in patients with advanced NSCLC.1 The most common treatment-related adverse events (AEs) were fatigue (19%), pruritus (17%), diarrhoea (15%), reduced appetite (14%) and rash (14%).1 14 patients (7%) experienced a treatment-related AE that led to treatment discontinuation, and 23% experienced a Grade 3/4 treatment-related AE.1 There was one treatment-related death (multifactorial hypoxia).1

Study 10: durvalumab + tremelimumab in patients with metastatic urothelial cancer
The combination of durvalumab plus tremelimumab showed clinical activity in previously treated mUC, regardless of PD-L1 status.3 Tumour and immune-cell PD-L1 expression was assessed with the Ventana PD-L1 (SP263) assay, PD-L1 cut-off: ≥25% of tumour and immune cells with membrane staining.2 The table below shows anti-tumour activity and survival by PD-L1 status.3

Response and survival PD-L1 ≥25%
(n=68)
PD-L1 <25%
(n=86)
PD-L1
unknown
(n=14)
Total
(N=168)
Confirmed Objective Response Rate (ORR)
(CR+PR) (95% CI), %
29.4 (19.0–41.7) 15.1 (8.3–24.5) 14.3 (1.8–42.8) 20.8 (15.0–27.8)
Ongoing ORR, % 60.0 92.3 100 74.3
Disease Control Rate (DCR)
(CR+PR+SD≥24 weeks) (95% CI), %
32.4 (21.5–44.8) 24.4 (15.8–34.9) 42.9 (17.7–71.1) 29.2 (22.4–36.7)
Median PFS, months (95% CI)
PFS 6-month rate
3.5 (1.9–3.7)
26.1
1.8 (1.8–1.9)
22.6
4.9 (1.8–NE)
38.5
1.9 (1.8–3.4)
25.4
Median OS, months (95% CI) *
OS 6-month rate
18.9 (8.1–NE)
66.4
8.0 (4.8–10.0)
51.9
16.4 (7.3–16.4)
91.7
9.5 (8.1–18.9)
60.9
NE = not estimable
*Should be interpreted with caution due to limited follow-up at data cut-off

The combination of durvalumab and tremelimumab demonstrated a manageable safety profile in patients with mUC.2 Treatment-related AEs occurred in 76% of patients and were Grade 3-4 in 29%.2 The most common treatment-related AEs were pruritus (26%), fatigue (24%), diarrhoea (20%), rash (14%) and increased lipase (12%). Treatment-related AEs led to discontinuation of therapy in 12% of patients.2 There was one treatment-related death (pulmonary haemorrhage).2

NOTES TO EDITORS

For more information on AstraZeneca at AACR, please visit www.twitter.com/AstraZeneca.

About Imfinzi
Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.4-7

In February 2018, durvalumab received US FDA approval for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Durvalumab also received accelerated approval in the US for the treatment of patients with locally advanced or metastatic urothelial carcinoma, who have disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery.8

As part of a broad development programme, durvalumab is also being investigated as a monotherapy and/or in combination with tremelimumab, an anti-CTLA-4 monoclonal antibody, as a first line treatment for patients with NSCLC, small cell lung cancer, locally advanced or metastatic urothelial carcinoma, head and neck cancer and other solid tumours.9

About tremelimumab
Tremelimumab is an investigational human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Tremelimumab blocks the activity of CTLA-4, contributing to T cell activation and boosting the immune response to cancer.10-12 Tremelimumab is being investigated in an extensive clinical trial programme in combination with durvalumab, in NSCLC, locally-advanced or metastatic urothelial carcinoma, head and neck cancer, liver cancer and blood cancers.9

About AstraZeneca’s Approach to Immuno-Oncology
Immuno-Oncology (IO) is a therapeutic approach designed to stimulate the body’s immune system to attack tumours. At AstraZeneca and MedImmune, our biologics research and development arm, our IO portfolio is anchored by immunotherapies that have been designed to overcome anti-tumour immune suppression. We believe that IO-based therapies will offer the potential for life-changing cancer treatments for the clear majority of patients.

We are pursuing a comprehensive clinical-trial programme that includes durvalumab (anti-PD-L1) as monotherapy and in combination with tremelimumab (anti-CTLA-4) in multiple tumour types, stages of disease, and lines of therapy, using the PD-L1 biomarker as a decision-making tool to define the best potential treatment path for a patient. In addition, the ability to combine our IO portfolio with small, targeted molecules from across our Oncology pipeline, and with those of our research partners, may provide new treatment options across a broad range of tumours.

About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a growth platform for AstraZeneca, focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and, one day, eliminate cancer as a cause of death.

About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of small-molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology; Respiratory; Cardiovascular, Renal & Metabolic Diseases; and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK, and Mountain View, CA. For more information, please visit www.medimmune.com.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company is also selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Intended audiences
This press release is issued from AstraZeneca Corporate Headquarters in Cambridge, UK and is intended to provide information about our global business for health specialist or medical media. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where AstraZeneca conducts business.

CONTACTS

Karen Birmingham +44 203 749 5634
Eleanor Duff +1 301 398 0967
Hugues Joublin +1 301 398 3041

References

  1. Chaft, J et al. Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC. To be presented at AACR 2018, April 14-18, 2018. Chicago, IL.
  2. Balar, A et al. Durvalumab + tremelimumab in patients with metastatic urothelial cancer. To be presented at AACR 2018, April 14-18, 2018. Chicago, IL.
  3. Balar, A et al. “Durvalumab + tremelimumab in patients with metastatic urothelial cancer.” Abstract. To be presented at AACR 2018, April 14-18, 2018. Chicago, IL.
  4. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody. Cancer Immunol Res; 2015. Published OnlineFirst May 5, 2015; doi: 10.1158/2326-606.
  5. Patel S P and Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther; 14(4) April 2015:847-856.
  6. Haile S et al. Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80. J Immunol 2011; 186: 6822-6829.
  7. Haile S et al. Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression. J Immunol 2013; 191: 2829-2836.
  8. US FDA. US Imfinzi (durvalumab) prescribing information. February 2018.
  9. AstraZeneca. Clinical Trials Appendix Full-year and Q4 2017 Results Update. Available at: https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20Clinical%20trials%20appendix.pdf. Accessed Apr. 2018
  10. Bograd AJ, et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother. 2011;60(11):1509-27.
  11. Lee et al. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol. 2013;76(2):233–47.
  12. Eroglu, et al. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015;51(17):2689-97

Macron, May questioned over Syria air strikes

Prime Minister Theresa May on Monday insisted last week’s strike on Syria was in Britain’s national interest as she explained to Parliament why she ordered the attack.

The Prime Minister faced questions from MPs who are angry she launched the military attack without securing the support of the Commons. Labour leader Jeremy Corbyn called on the Parliament to approve a regulation that would prevent the government from making military decisions without the approval of the Commons.

Members of France’s National Assembly expressed their displeasure at President Emmanuel Macron’s unilateral decision to attack Syria. They said President Macron failed to provide any proof of the Syrian government using chemical weapons.

The same day, White House press secretary Sarah Sanders said President Donald Trump wants to withdraw US forces from Syria, but no exact timeline was provided. She said Mr. Trump wants to meet with Russian President Vladimir Putin, but no plan has been devised.

Source: VOV5

Syria urges transparency, impartiality, accuracy in suspected chemical attack

Syria’s Deputy Foreign Minister Faisal Mekdad said Monday his government is ready to cooperate with the chemical weapons investigators of the Organization for the Prohibition of Chemical Weapons (OPCW).

Syria’s state news agency SANA reported that the inspectors arrived in Damascus 3 days ago and held meetings with the Syrian government to discuss transparent, impartial, and accurate cooperation. Mekdad said the Syrian government will create favorable conditions for the OPCW team to investigate the allegations of chemical weapons use by the Syrian army last week.

On Monday, Russia said it will not intervene in the investigation in Syria. The Kremlin called the UK’s accusation that Russia and Syria are blocking inspectors from reaching Douma groundless, stressing that Moscow always supports transparent investigations of suspected chemical attacks.

Source: VOV5

Syria urges transparency, impartiality, accuracy in suspected chemical attack

Syria’s Deputy Foreign Minister Faisal Mekdad said Monday his government is ready to cooperate with the chemical weapons investigators of the Organization for the Prohibition of Chemical Weapons (OPCW).

Syria’s state news agency SANA reported that the inspectors arrived in Damascus 3 days ago and held meetings with the Syrian government to discuss transparent, impartial, and accurate cooperation. Mekdad said the Syrian government will create favorable conditions for the OPCW team to investigate the allegations of chemical weapons use by the Syrian army last week.

On Monday, Russia said it will not intervene in the investigation in Syria. The Kremlin called the UK’s accusation that Russia and Syria are blocking inspectors from reaching Douma groundless, stressing that Moscow always supports transparent investigations of suspected chemical attacks.

Source: VOV5